GUTS

Fractyl Health, Inc.

An American medical company treating obesity and type 2 diabetes at their root. Its lead procedure, Revita, uses a heat-based endoscopic device to resurface the lining of the small intestine, helping people keep weight off after stopping GLP-1 drugs; its Rejuva platform delivers genes that reprogram insulin-making pancreatic cells. Founded in 2010 as MedCatalyst, the firm took its name from "fractal," echoing the repeating folds inside the intestine, and trades on Nasdaq as "GUTS."

CUSIP: 35168W103HealthcareUS1 holder

Ownership Activity Financials Filings

GUTS

GUTS

Results of Operations and Financial Condition

Regulation FD Disclosure

Submission of Matters to a Vote of Security Holders

Regulation FD Disclosure

Results of Operations and Financial Condition

Regulation FD Disclosure

Results of Operations and Financial Condition

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing